The purpose of the study is to evaluate the safety, tolerability and treatment effect of tirbanibulin ointment 1% when applied to a field of approximately 100 cm\^2 on the face or balding scalp.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 5
Timeframe: Baseline, Day 5
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 8
Timeframe: Baseline, Day 8
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 15
Timeframe: Baseline, Day 15
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 29
Timeframe: Baseline, Day 29
Number of Participants Categorized by Local Tolerability Score by Visit for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration) at Day 57
Timeframe: Baseline, Day 57
Number of Participants With Maximum Local Tolerability Score Post-baseline for Each Individual Signs (Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration)
Timeframe: Baseline, Maximum post-baseline (up to Day 57)
Time to Maximum Local Tolerability Score for Erythema, Flaking/Scaling, Crusting, Swelling, Vesiculation/Pustulation, and Erosion/Ulceration
Timeframe: Baseline up to Day 57
Local Tolerability Signs Total Composite Score by Visit at Day 5
Timeframe: Baseline, Day 5
Local Tolerability Signs Total Composite Score by Visit at Day 8
Timeframe: Baseline, Day 8
Local Tolerability Signs Total Composite Score by Visit at Day 15
Timeframe: Baseline, Day 15
Local Tolerability Signs Total Composite Score by Visit at Day 29
Timeframe: Baseline, Day 29
Local Tolerability Signs Total Composite Score by Visit at Day 57
Timeframe: Baseline, Day 57
Maximum Local Tolerability Signs Total Composite Score Post Baseline
Timeframe: Baseline, Maximum post-baseline (up to Day 57)
Time to Maximum Local Tolerability Total Composite Score
Timeframe: Baseline up to Day 57
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 5
Timeframe: Baseline, Day 5
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 8
Timeframe: Baseline, Day 8
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 15
Timeframe: Baseline, Day 15
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 29
Timeframe: Baseline, Day 29
Number of Participants With Pigmentation and Scarring in the Treatment Area by Visit at Day 57
Timeframe: Baseline, Day 57
Number of Participants With Any Treatment-emergent Adverse Events (TEAEs), Serious TEAEs and Adverse Events of Special Interest (AESIs)
Timeframe: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters
Timeframe: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Vital Signs
Timeframe: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Physical Examination
Timeframe: Baseline up to Day 57
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG)
Timeframe: Baseline up to Day 57